Press Detail

/
PRESS RELEASE

Successful start of the operation of the new plasma receiving area and the virological laboratories

- Authorities issue operating license for the building

- Storage capacity for human plasma expanded to 1,440 pallet slots

- Another milestone reached in the context of the Biotest Next Level capacity expansion programme

Dreieich, 10 December 2015. After just two years of construction, Biotest's new plasma receiving area and virological testing laboratories have been approved by Regional Authority Darmstadt and have been put into operation.

With highly automated logistics technology installed over 900 m², the plasma receiving area is state of the art. There are now 1,180 additional pallet slots at below -30 C on four levels covering 1,000 m² at the Dreieich production site. As a result, Biotest's in-house storage capacity in the deep-freeze area has increased from 260 to 1,440 pallets and now meets the future requirements of the ongoing "Biotest Next Level" capacity expansion scheme.

In synergy with this, 2,800 m² of state-of-the-art laboratory and office facilities have been constructed in the same building. They will be used by the virological laboratories for quality testing of human plasma and the pharmaceutical products manufactured from it. Now that operations are under way, processes are being further optimised and supplier dependence will be reduced. In terms of quality control, Biotest is thus prepared for the planned growth in volume in the years ahead.

The start of the operation of the new plasma receiving area and the virological laboratories means that another sub-project with a capital expenditure volume of more than EUR20 million within the "Biotest Next Level" capacity expansion scheme at the Dreieich location has been completed successfully and on schedule in 2015.

About Biotest

Biotest AG is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indication cancer of plasma cells and systemic lupus erythematosus (SLE), which are produced by recombinant technologies. Biotest has more than 2,200 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
email: investor_relations@biotest.de

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.